This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takiyyuddin, M. A. Articles by O'Connor, D. T. Search for Related Content PubMed PubMed Citation Articles by Takiyyuddin, M. A. Articles by O'Connor, D. T. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure

Hypertension, Vol 15, 237-246, Copyright © 1990 by American Heart Association

ARTICLES

Chromogranin A. Storage and release in hypertension

MA Takiyyuddin, JH Cervenka, RJ Hsiao, JA Barbosa, RJ Parmer and DT O'Connor
Department of Medicine, University of California, San Diego.

The chromogranins/secretogranins are a family of acidic, soluble proteins with widespread neuroendocrine distribution in secretory vesicles. Although the precise function of the chromogranins remains elusive, knowledge of their structure, distribution, and potential intracellular and extracellular roles, especially that of chromogranin A, has greatly expanded during recent years. Chromogranin A is coreleased with catecholamines by exocytosis from vesicles in the adrenal medulla and sympathetic nerve endings. Thus, measurement of its circulating concentration by radioimmunoassay may be a useful probe of exocytotic sympathoadrenal activity in humans, under both physiological and pathological conditions. Here, we explore the storage, structure, and function of chromogranin A, and parameters that influence its circulating levels. We have also measured plasma chromogranin A concentrations in different groups of patients with hypertension, including those with pheochromocytoma.

This article has been cited by other articles:

				J. R. Gayen, Y. Gu, D. T. O'Connor, and S. K. Mahata Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse Endocrinology, November 1, 2009; 150(11): 5027 - 5035. [Abstract] [Full Text] [PDF]

				N. Biswas, J. L. Rodriguez-Flores, M. Courel, J. R. Gayen, S. M. Vaingankar, M. Mahata, J. W. Torpey, L. Taupenot, D. T. O'Connor, and S. K. Mahata Cathepsin L Colocalizes with Chromogranin A in Chromaffin Vesicles to Generate Active Peptides Endocrinology, August 1, 2009; 150(8): 3547 - 3557. [Abstract] [Full Text] [PDF]

				K. A. S. Al-Shoumer and B. A. Vasanthy Serum Chromogranin A Concentration in Hyperthyroidism before and after Medical Treatment J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2321 - 2324. [Abstract] [Full Text] [PDF]

				Y. Chen, F. Rao, J. L. Rodriguez-Flores, M. Mahata, M. M. Fung, M. Stridsberg, S. M. Vaingankar, G. Wen, R. M. Salem, M. Das, et al. Naturally Occurring Human Genetic Variation in the 3'-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1468 - 1481. [Abstract] [Full Text] [PDF]

				T. A. Greenwood, F. Rao, M. Stridsberg, N. R. Mahapatra, M. Mahata, E. O. Lillie, S. K. Mahata, L. Taupenot, N. J. Schork, and D. T. O'Connor Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion Physiol Genomics, May 16, 2006; 25(3): 470 - 479. [Abstract] [Full Text] [PDF]

				K.C. Wollert and H. Drexler Chromogranin A in heart failure Eur. Heart J., June 2, 2002; 23(12): 926 - 927. [Full Text] [PDF]

				M. d'Herbomez, V. Gouze, D. Huglo, M. Nocaudie, F. Pattou, C. Proye, J.-L. Wemeau, and X. Marchandise Chromogranin A Assay and 131I-MIBG Scintigraphy for Diagnosis and Follow-Up of Pheochromocytoma J. Nucl. Med., July 1, 2001; 42(7): 993 - 997. [Abstract] [Full Text] [PDF]

				F. Rao, H. R. Keiser, and D. T. O'Connor Malignant Pheochromocytoma : Chromaffin Granule Transmitters and Response to Treatment Hypertension, December 1, 2000; 36(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K. Öberg, and B. Skogseid Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1 J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2712 - 2717. [Abstract] [Full Text]

				K. Tang, H. Wu, S. K. Mahata, and D. T. O'Connor A Crucial Role for the Mitogen-Activated Protein Kinase Pathway in Nicotinic Cholinergic Signaling to Secretory Protein Transcription in Pheochromocytoma Cells Mol. Pharmacol., July 1, 1998; 54(1): 59 - 69. [Abstract] [Full Text]

				R. J. Parmer, M. Mahata, S. Mahata, M. T. Sebald, D. T. O'Connor, and L. A. Miles Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway. CATECHOLAMINE STORAGE VESICLES AS A RESERVOIR FOR THE RAPID RELEASE OF t-PA J. Biol. Chem., January 17, 1997; 272(3): 1976 - 1982. [Abstract] [Full Text] [PDF]

				K. Tang, H. Wu, S. K. Mahata, L. Taupenot, D. J. Rozansky, R. J. Parmer, and D. T. O'Connor Stimulus-transcription Coupling in Pheochromocytoma Cells. PROMOTER REGION-SPECIFIC ACTIVATION OF CHROMOGRANIN A BIOSYNTHESIS J. Biol. Chem., November 8, 1996; 271(45): 28382 - 28390. [Abstract] [Full Text] [PDF]

				M. A. Takiyyuddin, R. J. Parmer, M. T. Kailasam, J. H. Cervenka, B. Kennedy, M. G. Ziegler, M.-C. Lin, J. Li, C. E. Grim, F. A. Wright, et al. Chromogranin A in Human Hypertension : Influence of Heredity Hypertension, July 1, 1995; 26(1): 213 - 220. [Abstract] [Full Text]